¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"thyroid hormone resistance syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
¿µ¹® Down syndrome ÇÑ±Û ´Ù¿îÁõÈıº
¼³¸í   
  »ç¶÷ÀÇ 46°³ ¿°»öü Áß Á¦ 21¹ø ¿°»öüÀÇ ¼ö°¡ 1°³ ´õ ¸¹¾ÆÁö¹Ç·Î½á ³ªÅ¸³ª´Â º´ÀÌ´Ù. È¯ÀÚÀÇ »ý±è»õ°¡ ¸¶Ä¡ ¸ù°í »ç¶÷°ú ´à¾Ò´Ù ÇÏ¿© ÀÏ¸í ¸ù°íÁõ(mongolism)À̶ó°í ÇÏ¿´À¸³ª À߸øµÈ À̸§ÀÌ´Ù. ÀÌ º´Àº ¹Ýµå½Ã 21¹ø ¿°»öü°¡ 3°³°¡ µÇ´Â °æ¿ìÀ̿ܿ¡µµ 21¹ø ¿°»öüÀÇ ÀϺκÐÀÌ ´Ù¸¥ ¿°»öüÀÇ ÀϺκаú ±³È¯ÀÌ µÇ´Â translocationÇü µîÀÇ ´Ù¸¥ ¿°»öüÀ̻󿡼­µµ º¼ ¼ö°¡ ÀÖ´Ù. ¹ß»ý ºóµµ´Â Ãâ»ý¾Æ 700~1000¸íÁß 1¸í ²Ã·Î ³ªÅ¸³ª¸ç, ¿°»öü À̻󺴠Áß¿¡ °¡Àå ¸¹Àº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ º´ÀÇ ¹ß»ýºóµµ´Â »ê¸ðÀÇ Ãâ»ê¿¬·É°ú ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ¾î, 35¼¼ ÀÌÈİ¡ µÇ¸é ±âÇÏ ±Þ¼öÀûÀ¸·Î ÀÌ ÁúȯÀÚÀÇ Ãâ»ê¼ö°¡ Áõ°¡ÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ Áúȯ¿¡ À־ ¾à 3ºÐÀÇ 1Àº ¸ðÄ£ÀÇ Ãâ»ê¿¬·É¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í, ³ª¸ÓÁö ¾à 3ºÐÀÇ 2´Â ¸ðÄ£ÀÇ ¿¬·É°ú Á÷Á¢ °ü·ÃÀÌ Àִ °ÍÀ¸·Î º¸°í ÀÖ´Ù. Áø´ÜÀº Æ¯Â¡ÀûÀΠ»ý±è»õ, Áï ¸ù°í »ç¶÷°°ÀÌ ´«²¿¸®°¡ À§·Î Ä¡ÄÑÁ® ÀÖ°í ´«°ÅÇ®ÀÌ µÎ²¨¿ì¸ç ÄàµîÀÌ ³·Àº Æ¯Â¡ÀûÀΠ¾ó±¼ ¸ð½À, ¶ÇÇÑ ±ÙÀ°ÀÇ ±äÀåµµ°¡ ÀúÇϵǰí Á¥À» ºü´Â Èû°ú ¿ïÀ½ ¼Ò¸®°¡ ¾àÇϸ砼չٴÚÀÇ Á¿츦 °¡¸£´Â ÇÑÁÙÀÇ ¼Õ±Ý(¿ø¼þÀ̿͠°°Àº ÇüÅÂÀÌ´Ù) µîÀǠƯ¡ÀûÀΠ¼Ò°ß¿¡ ÀÇÇØ º¸Á¶Áø´ÜÀ» Çϰí ÃÖÁ¾ÀûÀ¸·Î ¿°»öü ºÐ¼®¿¡ ÀÇÇØ È®ÁøÀ» ÇÑ´Ù. ÀÌ ´Ù¿îÁõÈıºÀǠȯÀڴ ´ë°³ Áö´ÉÀÌ ÀúÇϵǾî ÀÖ°í, ¿©·¯ °¡Áö Á¾·ùÀÇ ¼±Ãµ¼º ½ÉÀå±âÇüÀ» ¸¹ÀÌ µ¿¹ÝÇϰí ÀÖ´Ù.
¿µ¹® dumping syndrome ÇÑ±Û ´ýÇÎÁõÈıº
¼³¸í   
  ºÎºÐÀû À§ÀýÁ¦¼ú ¶Ç´Â À§ºóâÀÚ¿¬°á¼úÀ» ¹ÞÀº È¯ÀÚ¿¡°Ô¼­ À½½ÄÀ» ¸ÔÀº ÈÄ¿¡ ÀϾ´Â ÁõÈıºÀÌ´Ù. ¸íÄ¡ ºÎºÐÀÇ ÆØ¸¸°¨°ú ¾Ð¹Ú°¨-±¸¿ª-±¸Åä µîÀÇ º¹ºÎÁõ»ó ¿Ü¿¡ Å»·Â°¨-Çö±âÁõ-¹ßÇÑ-°¡½¿¶ê µî ¼øÈ¯Àå¾Ö Áõ»óÀÌ µû¸¥´Ù. ±×·± Áõ»óÀº ¼·ÃëÇÑ À½½Ä¹°ÀÌ À§¿¡¼­ ÀÛÀºÃ¢ÀڷΠÃß¶ôÇÏµí ¹èÃâµÊÀ¸·Î½á À½½Ä¹°ÀÇ ¹«°Ô·Î ÀÎÇØ ¼ÒÈ­°üÀÌ ¾Æ·¡ÂÊÀ¸·Î ÃÄÁ®µç´Ù. ÀÛÀºÃ¢ÀÚº®ÀÌ ±Þ°ÝÇϰԠ´Ã¾î³ªµç°¡, È­ÇÐÀû ÀÚ±ØÀ¸·Î ÀÎÇÑ ÀÛÀºÃ¢ÀÚº®ÀÇ ÀÚÀ²½Å°æ¹Ý»ç, ÀÛÀºÃ¢ÀÚº®ÀÇ »ïÅõ¾Ð¿¡ ÀÇÇØ ¼ÒÈ­°üÀ¸·Î ¼öºÐÀÌ ±Þ¼ÓÈ÷ ´ë·® À̵¿ÇÏ¿© ¼øÈ¯µÇ´Â Ç÷¾×ÀÇ ¾çÀÌ °¨¼ÒÇÏ¿© ÀϾ´Ù. ÁַΠ½Ä»ç¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©, ¾à¹°¿ä¹ýÀ¸·Î´Â ¾ÆÆ®·ÎÇÉ-Çí»ç¸ÞÅä´½-Æä³ë¹Ù¸£ºñÅ»-ź»ê¼ö¼Ò³ªÆ®·ýÀÇ »ç¿ë ¹× Æ÷µµ´çÁֻ絵 È¿°ú°¡ ÀÖ´Ù. ¼ö¼ú¿ä¹ýÀº ºô·Î½º(Billroth) Á¦1¹ýÀ¸·ÎÀÇ º¯È¯, ´ë¿ëÀ§ÀÇ Á¦ÀÛ µîÀÌ ÀÖÀ¸³ª È®½ÇÇÑ °ÍÀº ¾Æ´Ï´Ù.
¿µ¹® Raynaud syndrome ÇÑ±Û ·¹À̳ëÁõÈıº
¼³¸í   
  »çÁöÀÇ ´ëĪÀû Ã»»öÁõÀ» Æ¯Â¡À¸·Î Çϴ Áõ»óÀ¸·Î¼­ ¼Õ°¡¶ô-¼Õ¸ñ µîÀÇ ÇǺΰ¡ Áö¼ÓÀûÀ¸·Î Ã»»ö°ú Àû»öÀ¸·Î º¯Çϰí, ¼Õ°¡¶ôÀÇ ´ë·® ¶¡³²°ú ³Ã°¢À» ¼ö¹ÝÇÑ´Ù.
¿µ¹® battered child syndrome ÇÑ±Û ¸Å¸Â´Â ¾ÆÀÌ ÁõÈıº
¼³¸í   
  ¿µÀ¯¾Æ³ª ¼Ò¾Æ°¡ ºÎ¸ð µîÀÇ º¸À°ÀÚ³ª ÇüÁ¦ÀڸŷκÎÅÍ ¹Ýº¹Çؼ­ ½ÅüÀûÀΠÇд븦 ¹Þ¾Æ ¹ß»ýÇϴ °¢Á¾ Áõ»çÀÇ ÃÑĪÀÌ´Ù. 1962³â ÄÍÇÁ(Kempe)¿¡ ÀÇÇØ ¸í¸íµÇ¾ú´Ù. »ó󸦠¹ÞÀº ½Ã±â°¡ ¼­·Î Â÷À̰¡ Àִ ¿Ü»óÀÌ ¸ö Àüü ¿©·¯ °÷¿¡¼­ °üÂûµÇ´Â °ÍÀ̠Ư¡ÀÌ´Ù. ÇǺÎÀÇ ¼Õ»ó°ú ¾ó·èÃâÇ÷, °æÁú¸·ÇÏ Ç÷Á¾, °ñÀý µîÀÌ ¸¹°í ±Ø´ÜÀûÀΠ°æ¿ì´Â ¿µ±¸Àû ³ú¼Õ»ó°ú Á×À½¿¡ À̸£´Â °æ¿ìµµ ÀÖ´Ù. Çд뵿±â´Â ÇÇÇØÀÚ ÀÔÀå¿¡¼­´Â À°Ã¼Àû-Á¤½ÅÀû ¹ßÀ°ºÎÀü, ½ÖµÕÀÌ, ±âÇü, ¹ãÁß¿¡ ¿ì´Â °Í, ¾ß´¢Áõ, Àå³­, ¹ÝÇ×Àû Åµµ µîÀÌ ÀÖÀ¸¸ç °¡ÇØÀÚ ÀÔÀå¿¡¼­´Â º¸À°ÀÚÀÇ ¾ÆÀÌ¿¡ ´ëÇÑ ¾ÖÁ¤°áÇ̰ú °úÀ× ±â´ë, À°¾Æ¿¡ ´ëÇÑ ¹«Áö, ÇüÁ¦Àڸſ¡ ´ëÇÑ ½Ã»ù, Á¤½Åº´, ½Å°æÁõ, Áö´ÉÀúÇÏ, ¾ËÄڿàÁßµ¶ µîÀÌ ÀÖ°í, ¶Ç »ýȰȯ°æÀÇ ÀÔÀå¿¡¼­´Â ºó°ï, ºÎºÎ ºÒÈ­, ÇÙ°¡Á·À̸鼭 »çȸÀûÀ¸·Î °í¸³µÈ °¡Á¤ µîÀ» µé ¼ö ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û »ç½º
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. 
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • peripheral vascular resistance
    ¸»ÃÊÇ÷°üÀúÇ×
  • radiation resistance
    ¹æ»ç¼±ÀúÇ×
  • residual resistance
    ÀÜ·ùÀúÇ×
  • resistance
    1. ³»¼º 2. ÀúÇ× 3. ÀúÇ×¼º
  • resistance amplification
    ÀúÇ×ÁõÆø
  • resistance coil
    ÀúÇ×ÄÚÀÏ
  • resistance factor
    ³»¼ºÀÎÀÚ, ÀúÇ×ÀÎÀÚ
  • resistance furnace
    ÀúÇ×·Î
  • resistance plasmid
    ÀúÇ×Çö󽺹̵å
  • resistance reflex
    ÀúÇ׹ݻç
  • resistance transfer factor
    ³»¼ºÀü´ÞÀÎÀÚ
  • respiratory resistance
    È£ÈíÀúÇ×
  • vascular resistance
    Ç÷°üÀúÇ×
  • antidiuretic hormone
    Ç×ÀÌ´¢È£¸£¸ó
  • adrenal corticotropic hormone
    ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó, ºÎ½ÅÇÇÁúÀÚ±ØÈ£¸£¸ó
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • dry eye syndrome
    ´«¸¶¸§ÁõÈıº
  • dumping syndrome
    ºü¸¥ºñ¿òÁõÈıº, ´ýÇÎÁõÈıº
  • fetal alcohol syndrome
    žƾËÄÚ¿ÃÁõÈıº
  • Floppy infant syndrome
    Àú±äÀ徯ÁõÈıº, ±äÀåÀúÇÏ¿µ¾ÆÁõÈıº
  • Ganser syndrome
    °£ÀúÁõÈıº
  • Goodpasture's syndrome
    ±ÂÆÄ½ºÃ³ÁõÈıº
  • Guillain-Barre syndrome
    (¢¡acute idiopathic polyneuritis) ±Þ¼ºÆ¯¹ß´Ù¹ß½Å°æ¿° , ±Þ¼ºÆ¯¹ß¿©·¯½Å°æ¿°
  • hemolytic uremic syndrome
    ¿ëÇ÷¿äµ¶ÁõÈıº
  • hemorrhagic fever with renal syndrome
    ÃâÇ÷¿­ÄáÆÏÁõÈıº
  • hepatorenal syndrome
    °£ÄáÆÏÁõÈıº
  • irritable bowel syndrome
    °ú¹Î´ëÀåÁõÈıº
  • Kallmann syndrome
    Ä®¸¸ÁõÈıº
  • Klinefelter's syndrome
    Ŭ¶óÀÎÆçÅÍÁõÈıº
  • Korsakoff's syndrome
    ÄÚ¸£»çÄÚÇÁÁõÈıº
  • locked-in syndrome
    °¨±ÝÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • resistance furnace
    ÀúÇ×·Î
  • genetic resistance
    À¯ÀüÀúÇ×
  • heterogeneous resistance
    ºñ±ÕÀÏÀúÇ×
  • insulation resistance
    Àý¿¬ÀúÇ×
  • insulin resistance
    Àν¶¸°ÀúÇ×
  • internal resistance
    ³»ºÎÀúÇ×
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • natural resistance
    ÀÚ¿¬ÀúÇ×
  • one step high level resistance
    ÀÏȸ°íÀúÇ×ȹµæ
  • osmotic resistance
    »ïÅõ¾ÐÀúÇ×
  • peripheral resistance unit
    ¸»ÃÊÀúÇ×´ÜÀ§
  • peripheral vascular resistance
    ¸»ÃÊÇ÷°üÀúÇ×
  • pleiotropic resistance
    ´Ù¸é¹ßÇö¼ºÀúÇ×
  • progressive resistance
    Á¡ÁõÀúÇ×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • pulmonary vascular resistance
    ÆóÇ÷°üÀúÇ×(øËúìηî½ù÷), Æó¼øÈ¯ÀúÇ×.
  • radiation resistance
    ¹æ»ç¼±ÀúÇ×¼º
  • ACTH=£¾adrenocorticotropic hormone
    ºÎ½ÅÇÇÁúÀÚ±ØÈ£¸£¸ó
  • ADH =£¾antidiuretic hormone
    Ç×ÀÌ´¢È£¸£¸ó
  • CRH (corticotropin releasing hormone)
    ÄÚ¸£Æ¼ÄÚÆ®·ÎÇÉ ºÐºñÈ£¸£¸ó
  • Corticotropin releasing hormone
    ÄÚ¸£Æ¼ÄÚÆ®·ÎÇɺкñÈ£¸£¸ó
  • FSH= follicle stimulating hormone
    ³­Æ÷ÀÚ±Ø(Õ°øàí©Ð½)È£¸£¸ó.
  • FSH= follicle stimulating hormone
    ³­Æ÷ÀÚ±ØÈ£¸£¸ó.
  • Follicle-stimulation hormone
    ³­Æ÷ÀÚ±Ø(Õ°øàí©Ð½)È£¸£¸ó
  • GH= growth hormone
    ¼ºÀå È£¸£¸ó.
  • GH= growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó.
  • GH= growth hormone
    ¼ºÀåÈ£¸£¸ó.
  • GnRH (gonadotropin releasing hormone)
    ¼º¼±ÀÚ±Ø(àõàÍí©Ð½)È£¸£¸óºÐºñ(ÝÂÝô)È£¸£¸ó
  • Gonadotropic hormone
    ¼º¼±ÀÚ±Ø(àõàÍí©Ð½)È£¸£¸ó
  • Gonadotropin-releasing hormone (GnRH)
    ¼º¼±ÀÚ±Ø(àõàÍí©Ð½)È£¸£¸ó ºÐºñ(ÝÂÝô)È£¸£¸ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • heat resistance
    ³»¿­¼º(ËÀËçËÛ).
  • immunological resistance
    ¸é¿ªÀúÇ×.
  • index of resistance
    ÀúÇ×Áö¼ö(î½ù÷ò¦â¦).
  • insulation resistance
    Àý¿¬ÀúÇ×(ï¾æÞî½ù÷).
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • internal resistance =IR
    ³»ºÎÀúÇ×(Үݻî½ù÷).
  • intrinsic resistance
    º»Å¼º ³»¼º
  • loss of resistance method
    ÀúÇ׼ҽǹý
  • multidrug resistance gene family
  • multiple drug resistance
    ´ÙÁ¦³»¼º
  • multiple drug resistance gene
    º¹ÇÕ¾àÁ¦³»¼ºÀ¯ÀüÀÚ
  • natural resistance
    ÀÚ¿¬ÀúÇ×·Â(¼º)(í»æÔî½ù÷æ³àõ), ÀÚ¿¬³»¼º(~Ò±àõ).
  • one step high level resistance
    ÀÏ´Ü°è °íµµ ³»¼ºÈ¹µæ, ÀÏȸ °í³»¼ºÈ¹µæ
  • osmotic resistance
    »ïÅõ¾ÐÀúÇ×(¡­î½ù÷).
  • passive resistance
    Çǵ¿ÀúÇ×(ù¬ÔÑî½ù÷).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antidiuretic hormone
    Ç×ÀÌ´¢(ù÷××Òã)È£¸£¸ó
  • autocrine hormone
    ÀÚ°¡ºÐºñ (í»Ê«ÝÂÝô) È£¸£¸ó
  • brain hormone
    ³ú(Òà)È£¸£¸ó
  • chemotactic hormone
    È­ÇÐÁÖ¼º(ûùùÊñËàõ) È£¸£¸ó
  • corticotropin releasing hormone
    ÄÚ¸£Æ¼ÄÚÆ®·ÎÇÉ À¯¸®(ë´×î) È£¸£¸ó
  • diabetogenic hormone
    ´ç´¢º´¹ß»ý(ÓØÒãÜ»Û¡ßæ)È£¸£¸ó
  • eclosion hormone
    ¿ìÈ­(éâûù) È£¸£¸ó
  • emergency hormone
    ÀÀ±Þ(ëëÐá) È£¸£¸ó
  • female sex hormone
    ¿©¼º(Ò³àõ) ¼º(àõ)È£¸£¸ó
  • flowering hormone
    °³È­(ËÒü£) È£¸£¸ó
  • follicle-stimulating hormone
    ³­Æ÷ÀÚ±Ø(Õ°øàí©Ð½) È£¸£¸ó
  • gonadotrophic hormone
    ¼º¼±ÀÚ±Ø(àõàÍí©Ð½)È£¸£¸ó
  • gonadotropic hormone
    ¼º¼±ÀÚ±Ø(àõàÍí©Ð½)È£¸£¸ó
  • gonadotropin releasing hormone
    °í³ªµµÆ®·ÎÇÉ ¹æÃâ(Û¯õó)È£¸£¸ó
  • growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • lateral recess syndrome
    ¿ÜÃøÇÔ¿äÁõÈıº
  • Loeffler's eosinophilic syndrome
    ·ÚÇ÷¯È£»ê±¸ÁõÈıº
  • malabsorption syndrome
    Èí¼öÀå¾ÖÁõÈıº
  • Marfan's syndrome
    ¸¶¸£ÆÎÁõÈıº
  • medial medullary syndrome
    ³»Ãø¿¬¼öÁõÈıº
  • Meniere's syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • middle lobe syndrome
    Áß¿±ÁõÈıº
  • mucocutaneous lymph node syndrome
    ÇǺÎÁ¡¸·¸²ÇÁÀýÁõÈıº
  • mucocutaneous ocular syndrome
    ÇǺÎÁ¡¸·¾ÈÁõÈıº
  • nephrotic syndrome
    ½ÅÁõÈıº, ³×ÇÁ·Î½Ã½ºÁõÈıº
  • omental adhesion syndrome
    ´ë¸Á¸·À¯ÂøÁõÈıº
  • overlap syndrome
    ÁßøÁõÈıº
  • Pancoast syndrome
    ÆÇÄÚ½ºÆ® ½Åµå·Ò
  • parietooccipital syndrome
    µÎÁ¤¿±Èĵο±ÁõÈıº
  • peutz-Jegher's syndrome
    Æ÷ÀÌÃ÷-¿¹°ÅÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
TSR theophylline sustained release; thyroid to serum ratio; total systemic resistance
EPR early progressive resistance; electron paramagnetic resonance; electronic patient record; electrophr...
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
PVR peripheral vascular resistance; perspective volume rendering; poliovirus receptor; postvoiding resid...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TR alpha thyroid hormone receptor alpha
TRE thyroid hormone responsive element
TRH thyroid releasing hormone
TSHr thyroid simulating hormone receptor
APC resistance Resistance to activated protein C
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adrenocorticotropic hormone
    ºÎ½Å ÇÇÁú ÀÚ±Ø È£¸£¸ó
    ³úÇϼöü Àü¿±¿¡¼­ »ý¼º, ºÐºñµÇ¾î ºÎ½Å ÇÇÁú¿¡ ÀÛ¿ëÇØ¼­ ÄÚÆ¼¼Ö ¹× ÄÚÆ¼ÄÚ½ºÅ×·ÐÀÇ ºÐºñ¸¦ ÃËÁøÇϴ ȣ¸£¸ó. ½ºÆ®·¹½º ½Ã¿¡ ½Ã»óÇϺο¡ ÈïºÐÀÌ ÀϾ Á¤Áß À¶±â¿¡¼­ ºÎ½Å ÇÇÁú ÀÚ±Ø È£¸£¸ó ¹æÃâ ÀÎÀÚ°¡ ¸ÕÀú ºÐºñµÇ¸é À̰ÍÀÌ ³úÇϼöü ¹®¸ÆÀ» ÅëÇØ¼­ ³úÇϼöü Àü¿±¿¡ µµ´ÞÇÏ¿© °Å±â¿¡¼­ ACTHÀÇ »ý¼º ¹× ºÐºñ¸¦ ÃËÁøÇÑ´Ù.
  • adrenomedullary hormone
    ºÎ½Å ¼öÁú È£¸£¸ó
  • antidiuretic hormone
    Ç×ÀÌ´¢ È£¸£¸ó
    ADH-vaso
  • chromatophoriotropic hormone
    Çâ»ö¼Ò º¸À¯ ¼¼Æ÷ È£¸£¸ó
  • cortical hormone
    ÇÇÁú È£¸£¸ó
  • corticosteroid hormone
    ÄÚÆ¼ÄÚ½ºÅ×·ÎÀ̵å È£¸£¸ó
  • female hormone
    ¿©¼º È£¸£¸ó
    ôÃß µ¿¹° ¾ÏÄÆÀÇ ³­¼Ò¿¡¼­ ºÐºñµÇ¾î ¼º±âÀÇ ¹ßÀ°°ú »ý½Ä±â´É Á¶Àý µî¿¡ ÀÛ¿ëÇÏ´Â ¼º È£¸£¸ó. ³­¼Ò È£¸£¸óÀ̶ó°íµµ ÇÑ´Ù. ¿©Æ÷¿¡¼­ ³ª¿À´Â ¿©Æ÷ È£¸£¸ó°ú Ȳü¿¡¼­ ³ª¿À´Â Ȳü È£¸£¸óÀÌ ÀÖ´Ù. ÀÇ¾à ¹æ¸é¿¡¼­ º¸Åë ¿©¼º È£¸£¸óÀ̶ó°í ÇÒ ¶§´Â ¿©Æ÷ È£¸£¸óÀ» ¸»ÇÑ´Ù. ¿©Æ÷ È£¸£¸óÀº ¹ßÁ¤ È£¸£¸óÀ¸·Î ¿©¼º »ý½Ä±âÀÇ ¹ßÀ°À» ÃËÁøÇÏ¿© ¿©¼º´Ù¿òÀ» ÁõÁø½ÃŲ´Ù. Ȳü È£¸£¸óÀº ¹ßÁ¤ È£¸£¸ó¿¡ ±æÇ×ÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¹ßÁ¤À» ¾ïÁ¦ÇÑ´Ù. À̵é È£¸£¸óÁ¦ÀÇ »ç¿ëÀº ÀÎü¿¡ ÀÌ»óÇÑ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ¼ö°¡ ÀÖÀ¸¹Ç·Î ±× »ç¿ëÀº ¹Ýµå½Ã Àü¹® ÀÇ»çÀÇ Áö½Ã¿¡ µû¶ó¾ß ÇÑ´Ù. ¹ßÁ¤ È£¸£¸óÀÇ ÀÛ¿ëÀ» °¡Áø ¹°ÁúÀ» ÃÑÄªÇØ¼­ ¿¡½ºÆ®·Î°Õ
  • follicle stimulating hormone releasing factor
    ³­Æ÷ ÀÚ±Ø È£¸£¸ó ¹æÃâ ÀÎÀÚ
  • follicular hormone
    ¿©Æ÷ È£¸£¸ó
    ôÃßµ¿¹°ÀÇ ³­¼Ò ¾È¿¡ ÀÖ´Â ³­Æ÷¿¡¼­ ºÐºñµÇ´Â ÀÚ¼º È£¸£¸ó. ³­Æ÷ È£¸£¸ó, ¹ßÁ¤ È£¸£¸óÀ̶ó°íµµ ÇÑ´Ù. »ý½Ä±â¸¦ ¹ßÀ°½ÃŰ°í ±× ±â´ÉÀ» ³ªÅ¸³»µµ·Ï ÇÏ¿© Á¦2Â÷ ¶Ç´Â Á¦3Â÷ ¼ºÂ¡À» ¹ß´Þ½Ã۴µ¥, ƯÈ÷ Æ÷À¯·ù¿¡¼­ ¹ßÁ¤À» ÀÏÀ¸Å°°Ô ÇÏ´Â µ¥¼­ ¹ßÁ¤ È£¸£¸óÀ̶ó´Â À̸§ÀÌ ºÙ¾ú´Ù. ³­¼Ò À̿ܿ¡µµ ŹÝÀ» ºñ·ÔÇÏ¿© ºÎ½Å ÇÇÁúÀ̳ª Á¤¼Ò·ÎºÎÅÍ ¼Ò·® ºÐºñµÇ´Âµ¥ ¿¡½ºÆ®·ÐÀ̳ª ¿¡½ºÆ®¶óµð¿Ã ¹× ÀÎü¿¡¼­ º¼ ¼ö ÀÖ´Â ¿¡½ºÆ®¸®¿Ã µî 3Á¾·ùÀÇ ½ºÅ×·ÎÀ̵尡 ¾Ë·ÁÁ® ÀÖ´Ù. È­ÇÐÀûÀ¸·Î ¾ÈÁ¤µÇ¾î ÀÖÀ¸¸ç Àڱà ¹ßÀ°, ³»¸· Áõ½Ä, Á¥»ù ¹ßÀ°, ±ÔÄ¢Àû ¿ù°æ, Á¦2Â÷ ¼ºÂ¡ µîÀ» ÃËÁøÇÑ´Ù. ÀÌ È£¸£¸óÀÇ ºÐºñ´Â ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â ¿©Æ÷ ÀÚ±Ø È£¸£¸ó
  • hormone antagonist
    Ç×È£¸£¸ó ¾à, Ç×È£¸£¸ó ¹°Áú
  • hormone dependent tumor
    È£¸£¸ó ÀÇÁ¸¼º Á¾¾ç
  • hormone like action
    È£¸£¸ó À¯»ç ÀÛ¿ë
    ü³»¿¡ µé¾î¿Í È£¸£¸ó°ú ºñ½ÁÇÑ ¿ªÇÒÀ» ÇÏ´Â °Í.
  • hormone recenptor
    È£¸£¸ó ¼ö¿ëü
    È£¸£¸óÀÌ ÀÛ¿ëÇÏ´Â ºÎÀ§¿¡¼­ È£¸£¸óÀÌ °áÇÕÇÏ´Â °÷.
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • hypothalamic hormone
    ½Ã»ó ÇϺΠȣ¸£¸ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
chloramphenicol resistance <microbiology, pharmacology> Nonsusceptibility of a bacterium to the action of chloramphenicol, a potent inhibitor of protein synthesis in the 50s ribosomal subunit where amino acids are added to nascent bacterial polypeptides.
(12 Dec 1998)
methicillin resistance Non-susceptibility of a microbe to the action of methicillin, a semi-synthetic penicillin derivative.
(12 Dec 1998)
multidrug resistance The insensitivity of various tumours to a variety of chemically related anticancer drugs; mediated by a process of inactivating the drug or removing it from the target tumour cells.
(05 Mar 2000)
mutual resistance An interaction between chemicals in which one partially or completelyinhibits the effect of the other (for example, a drug that blocks a hormone's receptor site would be a hormone antagonist).
(09 Oct 1997)
cross-resistance <immunology, microbiology> Immunologic resistance to the pathogenic effects of a microorganism because of previous exposure to another species or type having cross reactive antigens.
This phenomenon is seen in microbes that acquire resistance to one drug through direct exposure and turn out to have resistance to one or more other drugs to which it has not been exposed. Cross-resistance arises because the mechanism of resistance to several drugs is the same and arises through the identical genetic mutations.
(09 Oct 1997)
sisomicin-gentamicin resistance ribosomal RNA methylase <enzyme> Catalyses the methylation of 30s ribosomal units to confer sisomicin-gentamicin resistance in micromonospora zionensis
Registry number: EC 2.1.1.-
Synonym: sgm gene product, sgm methylase
(26 Jun 1999)
synaptic resistance The ease or difficulty with which a nerve impulse can cross a synapse.
(05 Mar 2000)
systemic vascular resistance An index of arteriolar compliance or constriction throughout the body; equal to the blood pressure divided by the cardiac output.
(05 Mar 2000)
dicumarol resistance A well-defined autosomal dominant resistance to it, over and above general variability in tolerance to the drug.
(05 Mar 2000)
drug resistance The ability of bacteria and other microorganisms to withstand a drug to which they were once sensitive (and were once stalled or killed outright).
(12 Dec 1998)
drug resistance, microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through plasmids containing resistance factors (r factors).
(12 Dec 1998)
drug resistance, multiple Simultaneous resistance to a broad spectrum of structurally and functionally distinct drugs following exposure to a single agent. It is thought to result from the overexpression of genes encoding an integral plasma membrane protein, p-glycoprotein.
(12 Dec 1998)
drug resistance, neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
(12 Dec 1998)
impact resistance The ability of a lens for eyewear to withstand impact without shattering or breaking, i.e., of a 3/8 -inch steel ball dropped 50 feet; criteria for determination of impact resistance are specified by U.S. Regulations.
(05 Mar 2000)
inductive resistance The weakening of an alternating electric current by passage through a coil of wire or a condenser.
Synonym: inductive resistance.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á